Modulation of Platelet Activation and Thrombus Formation Using a Pan-PI3K Inhibitor S14161

Wenxiu Yi¹, Qiang Li¹, Jian Shen¹, Lijie Ren¹, Xiaohui Liu¹, Qi Wang¹, Sudan He¹, Qingyu Wu¹, Hu Hu², Xinliang Mao¹, Li Zhu¹

¹ Cyrus Tang Hematology Center, Collaborative Innovation Center of Hematology, MOH Key Lab of Thrombosis and Hemostasis, Jiangsu Institute of Hematology, the First Affiliated Hospital, Soochow University, Suzhou, China, ²Department of Pathology and Pathophysiology, Zhejiang University, Hangzhou, China

Abstract

The phosphatidylinositol 3–kinase (PI3K) signaling pathway is critical in modulating platelet functions. In the present study, we evaluated the effect of S14161, a recently identified pan-class I PI3K inhibitor, on platelet activation and thrombus formation. Results showed that S14161 inhibited human platelet aggregation induced by collagen, thrombin, U46619, and ADP in a dose-dependent manner. Flow cytometric studies showed that S14161 inhibited convulxin- or thrombin-induced P-selectin expression and fibrinogen binding of single platelet. S14161 also inhibited platelet spreading on fibrinogen and clot retraction, processes mediated by outside-in signaling. Using a microfluidic chamber we demonstrated that S14161 decreased platelet adhesion on collagen-coated surface by about 80%. Western blot showed that S14161 inhibited phosphorylation of Akt at both Ser473 and Thr308 sites, and GSK3β at Ser9 in response to collagen, thrombin, or U46619. Comparable studies showed that S14161 has a higher potential bioavailability than LY294002, a prototypical inhibitor of pan-class I PI3K. Finally, the effects of S14161 on thrombus formation in vivo were measured using a ferric chloride-induced carotid artery injury model in mice. The intraperitoneal injection of S14161 (2 mg/kg) to male C57BL/6 mice significantly extended the first occlusion time (5.05 ± 0.99 min, n = 9) compared to the vehicle controls (3.72 ± 0.95 min, n = 8) (P < 0.05), but did not prolong the bleeding time (P > 0.05). Taken together, our data showed that S14161 inhibits platelet activation and thrombus formation without significant bleeding tendency and toxicity, and considering its potential higher bioavailability, it may be developed as a novel therapeutic agent for the prevention of thrombotic disorders.

Introduction

Platelets play a critical role in atherothrombosis that leads to myocardial infarction and ischemic stroke [1,2]. Once vascular injury occurs, the binding of the platelet glycoprotein (GP)IIb complex to von Willebrand factor (VWF) on the injured vessel wall initiates platelet tethering and subsequent adhesion [3]. The exposed collagen in the vascular wall and locally generated thrombin activate platelets and initiate hemostasis. The binding of collagen to GPVI on platelets results in receptor clustering and thereby stimulates phosphorylation of specific tyrosine residues within an associated trans-membrane protein, the Fc receptor γ-chain (FcγRγ-chain). This leads to the recruitment of signaling proteins such as Src kinase, the tyrosine kinase Syk, PLCγ2, phosphatidylinositol 3-kinase (PI3K) and mitogen activated protein kinases (MAPKs), resulting in the inside-out activation of the integrin αIIbβ3 and the release of the secondary mediators, such as ADP and thromboxane A2 (TXA2), culminating in platelet aggregation mediated by fibrinogen [4,5], or other ligands binding to αIIbβ3 [6,7]. The modulation of platelet activity using specific pharmacological agents has proven to be a successful strategy for the prevention of thrombosis. The successful introduction of antiplatelet drugs, such as antagonists of ADP and αIIbβ3, and inhibitors of COX-1 and phosphodiesterase, has led to considerable improvements in the management of cardiovascular diseases [8]. However, the risk of uncontrolled bleeding due to their inherent antihemostatic effects limited their clinical use [9]. Therefore, tremendous effort has been made in the past years on the identification of novel pharmacological reagents with both effective and safe antiplatelet effect.

The recent search for compounds to prevent platelet activation has been focusing on the ones that modulate PI3K pathway, PI3K is a critical transmitter of intracellular signaling during platelet activation [10–12], capable of triggering a wide variety of responses like phosphorylation of pleckstrin, activation of PLCγ [13], Rap1b and AKT [14–17], and mediating several important platelet responses like platelet shape change and stabilization of platelet aggregation [18]. Platelets contain PI3K class IA (p110α), class IB (p110β and p110δ), class IB (p110γ), and class II (C2γ) [19]. Knock-out mouse models showed that PI3Kγ acts as an important effector of P2Y12 while PI3K-IA as a key effector of collagen receptors [10,12]. PI3K activation leads to the phosphorylation of AKT or protein kinase B, which is a critical player in platelet...
function [20,21]. Targeting the PI3K/AKT is thus becoming an emerging strategy in the control of platelet-associated diseases. So far, more than 50 inhibitors for the PI3K/AKT/mTOR pathway are under clinical evaluation at different phases [22]. However, none of these PI3K inhibitors has been approved for modulating platelet activation and thrombus formation clinically.

We recently identified S14161, or 8-ethoxy-2-(4-fluorophenyl)-3-nitro-2H-chromene, as a novel PI3K inhibitor, that displays promising effects against multiple myeloma and leukemia cells with minimal toxicity [23]. However, whether S14161 affects platelet activation and thrombus formation is unknown. Therefore, in this study, we investigated the effect of S14161 on platelet activation in response to a variety of agonists and thrombus formation. We showed that S14161 significantly inhibited agonist-induced platelet activation and thrombus formation via inhibiting PI3K/AKT pathway.

Methods and Materials

Animals and human samples

All animal procedures were approved by the University Committee on Animal Care of Soochow University (20140431) and each researcher followed the approved procedures when caring for or sacrificing mice and when conducting protocols involving mice. C57BL/6 mice were housed at a constant room temperature, humidity, and light cycle (12:12 hr light-dark) with free access to water and were fed chow diet. After 6–8 weeks, mice were randomly grouped into S14161- or vehicle-treated groups. Anesthesia using 7% chloral hydrate was applied to avoid any pain of animals during procedures. After the experiments, the animals were euthanized by CO2 inhalation. Human venous blood was obtained from healthy donors in accordance with the Declaration of Helsinki and the permission from the University ethical committee of Soochow University. The written informed consent was obtained from all participants.

Reagents

S14161 was synthesized and purified by high performance liquid chromatography (HPLC) as reported previously [24]. Collagen, thrombin, and ADP were purchased from Chrono-Log Corp (Hatertown, PA, USA). U46619 was purchased from Calbiochem (La Jolla, CA, USA). Antibodies against AKT, phospho-AKT Thr308, phospho-AKT Ser473, phospho-GSK3β Ser9, were purchased from Cell Signaling Technologies (Danvers, MA). The pan-PI3K inhibitor LY294002 was from Beyotime (Nantong, China). TRITC-Phalloidin was from Sigma-Aldrich (St. Louis, MO, USA). PE-conjugated anti-human CD62P (BD Biosciences, Lincoln, NE, USA). Secondary antibody (goat anti-rabbit IRDye 800CW or goat anti-mouse IRDye 800CW) was purchased from LI-COR Biosciences, Lincoln, NE, USA.

Platelet isolation and aggregation

Human venous blood was obtained from healthy donors and anticoagulated 1:5 with ACD (65 mM Na3 citrate, 70 mM citric acid, 100 mM dextrose, pH 4.4). Platelet-rich plasma (PRP) was obtained by centrifuging at 900 rpm for 20 minutes [25]. Gel-filtered platelets were prepared as described previously [26]. Briefly, PRP was applied to the column that was packed with Sepharose 2B beads in phosphate-buffer saline (PBS) in a column and the column was washed with Tyrode’s buffer to a series of 1.5-ml tubes. The collected platelets in each tube were counted, combined, and adjusted to 2.5×10^8/mL using Tyrode’s buffer. Platelet aggregation was performed in a ChronoLog aggregometer (Havertown, PA). Platelets were preincubated with vehicle or S14161 for 10 min at 37°C in a cuvette. Before adding agonists, CaCl2 (1 mM) and fibrinogen (200 μg/ml) were added. Aggregation assay was started with 0% aggregation baseline and then an agonist was added to observe the percentage of platelet aggregation with stirring at 900 rpm.

Platelet viability assay

Platelet viability assay was described as previously [27] and AlamarBlue cell viability reagent was used as described by the vendor’s manual (Invitrogen, Carlsbad, CA, USA). Briefly, gel-filtered platelets (2.5×10^7/ml) were preincubated with S14161 or vehicle and then incubated with AlamarBlue reagent for 4 hours at 37°C. Upon entering cells, resazurin, a compound that is red in color and highly fluorescent. When platelets are alive they maintain a reducing environment within the cytosol and the generated fluorescence was acquired on a SpectraMax Microplate Reader (Molecular Devices, Sunnyvale, CA, USA). The excitation and emission wavelengths were 570 nm and 585 nm, respectively. Tyrode buffer was used as a background control.

Phosphatidylserine (PS) Externalization Assay

PS Externalization Assay was performed as previously described [27]. Gel-filtered platelets (2×10^7/ml) were preincubated with S14161 or dibucaine (500 μmol/ml) at room temperature for 15 min. Annexin V binding buffer (0.01 M HEPES, pH 7.4, 0.14 M NaCl, 2.5 mM CaCl2) was mixed with pre-treated platelets and Annexin V-APC at a 50:50:1 ratio. Samples were gently mixed and incubated at room temperature for 15 min in the dark before being analyzed on a flow cytometer (FACSCaliburM, Becton Dickinson, San Jose, CA, USA).

Immunoblotting

Aliquots of gel-filtered platelets (250 μl, 2.5×10^7/ml) were preincubated with vehicle or S14161 for 10 minutes and stimulated by agonists under stirring at 37°C. The reaction was stopped by adding RIPA buffer (1% Triton X-100, 1% deoxycholate, 0.1% SDS, 10 mM Tris, 150 mM NaCl containing protease inhibitors and phosphatase inhibitors). After heating to 100°C for 10 minutes, proteins were separated on 10% SDS polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose membrane (Bio-Rad). The membrane was incubated with antibodies at 4°C overnight followed by a corresponding secondary antibody (goat anti-rabbit IRDye 800CW or goat anti-mouse IRDye 800CW). The densitometric band scanning was performed using Odyssey infrared imaging system (LI-COR Biosciences, Lincoln, NE, USA).

Soluble fibrinogen binding and P-selectin expression

Gel-filtered human platelets were adjusted to 2×10^7/ml by adding Tyrode’s buffer, and were incubated with or without S14161 (10 μM) for 10 minutes at 37°C. The platelets were then stimulated with convulxin or thrombin in the presence of FITC-labeled fibrinogen or PE-labeled CD62P at room temperature for 15 minutes and immediately fixed with 4% paraformaldehyde. Platelet-bound fluorescence was analyzed using a BD FACS Calibur Flow Cytometer.

Platelet spreading on immobilized fibrinogen

Glass coverslips were coated with 10 μg/ml fibrinogen in 0.1 M NaHCO3 (pH 8.3) by soaking at 4°C overnight, and then washed with PBS. After incubation with or without S14161 at 37°C for 30 minutes, 2×10^7/ml platelets in Tyrode’s buffer were allowed to spread on the fibrinogen coated coverslips for 60 minutes at 37°C.
S14161 Inhibits Platelet Activation and Thrombus Formation

**A**

50% Aggregation (\%)

- Coll (50%)
- Thr (50%)
- U46619 (50%)
- ADP (50%)



---

**B**

Aggregation (%)

- Coll (2μg/ml)
- Thrombin (0.1U/ml)
- U46619 (1μM)
- ADP (10μM)



---

**C**

Aggregation (%)

- Coll (2μg/ml)
- Thrombin (0.1U/ml)
- U46619 (1μM)
- ADP (10μM)



---

**D**

Aggregation (%)

- Coll (2μg/ml)
- Thrombin (0.1U/ml)
- U46619 (1μM)
- ADP (10μM)
Figure 1. S14161 inhibited platelet aggregation. Gel-filtered human platelets (2.5 × 10^6/mL) were preincubated for 10 minutes with different concentrations of S14161 (2.5 μM, 5 μM and 10 μM) or vehicle (DMSO). Platelet aggregation was initiated with collagen (2 μg/mL), thrombin (0.1 U/mL), U46619 (1 μM), or ADP (10 μM). The aggregation curves are the representatives of at least three individual experiments. Means ± standard errors of the mean of platelet aggregation percentage from three experiments are plotted in the bar charts; *P < 0.05, **P < 0.01 and ***P < 0.001 as compared with control. N.S. means no significance (n = 3).

doi:10.1371/journal.pone.0102394.g001

After washed five times with PBS, adherent platelets were fixed with 4% paraformaldehyde, and stained with TRITC-labeled phalloidin containing 0.1% Triton X-100 at room temperature for 2 hours. Coverslips were mounted on the slides, and platelet spreading was observed under a fluorescence microscope (Olympus, FSX100).

Clot retraction

As previously described [28], platelet-rich plasma (3 × 10^8 platelets/mL) obtained by centrifugation of whole blood at 900 rpm for 20 minutes was incubated with S14161 for 30 minutes at 37°C. Fibrinogen was then added to a final concentration of 2 mg/mL, and the PRP were dispensed in 0.25 mL aliquots in 0.25 mL aliquots into siliconized glass tubes. Clot retraction was initiated by 1 U/mL of thrombin and allowed to proceed at 37°C. Clot retraction was monitored at indicated time points using a digital camera. The extent of retraction was quantified using Image J software developed by National Health Institute (Bethesda, MD).

Microfluidics chamber

The human whole blood was used for platelet adhesion assay under flow. The experiments were performed as described previously [26,29] using BioFlux 200 setup (Fluxion Biosciences, USA) following manufacturer’s instruction. Briefly, the channels were primed and coated with collagen I (200 μg/mL) for 1 hour at room temperature and then blocked with PBS containing 0.5% BSA for 1 hour. The human whole blood was treated with S14161 or vehicle and labeled with calcine-AM (Molecular Probes, Eugene, OR, USA) at a final concentration of 4 mM for 30 minutes at room temperature. Blood was perfused in the channels at 1000 s⁻¹ and observed under a fluorescent microscope for platelet adhesion and aggregates.

FeCl₃-induced carotid artery injury model

FeCl₃-induced carotid artery injury was performed as previously described with some modifications [27,29,30]. Briefly, S14161 (2 mg/kg) or vehicle was administered intraperitoneally to mice (C57BL/6, age 6–8 weeks), and after anesthesia using 7% chloral hydrate, the left carotid artery was surgically exposed by blunt dissection. A 1.0 × 0.2×0.0-mm filter paper soaked in 7.5% FeCl₃ was applied to the surface of the adventitia of the exposed artery for two minutes. After removal of the filter paper, the artery was washed with PBS and an imaging ultrasound gel (MS400-0090; VisualSonics) was placed in the surgical wound to allow Doppler monitoring. The artery was identified using a small animal blood flow transducer (MS400, 18–38 MHz; VisualSonics) and the color Doppler mode of the VisualSonics Vevo model 2100 flowmeter. Time to occlusion of the carotid artery after the application of 7.5% FeCl₃ was measured using Visual Sonics View 2100. The operator was blinded to mice that infused either S14161 or vehicle while performing all experiments.

Tail bleeding time in mice

Tail bleeding time were determined as previously described [27]. Briefly, S14161 or vehicle was administered intraperitoneally to mice (C57BL/6, age 6–8 weeks). Forty-five minutes later, mice were anesthetized with 7% chloral hydrate and placed prone on a heating pad from which the tail protruded. The distal 5 mm of the tail was transected and immediately immersed in 12 ml 0.9% sodium chloride for 10 min at 37°C, and the time to bleeding cessation was recorded.

Statistical analysis

Data were analyzed by using GraphPad Prism 5.0 software and presented as means ± standard error of the mean. The statistical significance was determined by one-way ANOVA analysis of variance with the Bonferroni post test for multiple groups. The Student t test was used to calculate P values for differences. Differences were considered significant at P < 0.05.

Results

S14161 inhibits platelet aggregation

PI3K is critical in mediating platelet activation by a variety of agonists and targeting PI3K could be a promising strategy in the treatment of diseases in association of overactivated platelets and prothrombotic condition. Therefore, we asked whether S14161 is able to suppress platelet activation and thrombus formation. We first examined the potential effect of S14161 on platelet aggregation. Gel-filtered human platelets were incubated with S14161 (2.5, 5 and 10 μM) or solvent alone for 10 minutes at 37°C and then stimulated with collagen (2 μg/mL), ADP (10 μmol/L), U46619 (1 μmol/L), or thrombin (0.1 U/mL). As shown in Figure 1, platelet aggregation triggered by all these four agents was inhibited by S14161 in a dose-dependent manner. For example, the maximal aggregation induced by collagen were decreased by 32.7% (P < 0.05), 59.4% (P < 0.001) and 89.2% (P < 0.001) when preincubated with 2.5, 5 and 10 μM of S14161, respectively (Fig. 1A). The IC₅₀s of S14161 in inhibiting agonist-induced platelet aggregation were 3.79 ± 1.17 (μM) for collagen (2 μg/mL), 6.32 ± 0.51 (μM) for thrombin (0.1 U/mL), and 1.38 ± 0.97 (μM) for U46619 (1 μM). S14161 also inhibited platelet aggregation induced by GPVI selective ligand convulxin and CRP, PAR1 agonist SFLLRN, and calcium ionophore A23187 (data not shown).

To compare the inhibition potency of S14161 with LY249002 in platelet aggregation, we also examined LY249002 effect on inhibiting human platelet aggregation induced by collagen (Fig. 2A), thrombin (Fig. 2B), and U46619 (data not shown). To our surprise, LY249002 showed weaker inhibition as compared with S14161, and the IC₅₀s of LY249002 in inhibiting platelet aggregation were much higher than S14161, which are 14.19 ± 1.38 (μM) for collagen (2 μg/mL), 35.12 ± 4.21 (μM) for thrombin (0.1 U/mL), and 25.12 ± 3.72 (μM) for U46619 (1 μM). To further confirm this, we compared the ability of S14161 and LY249002 in inhibiting platelet aggregation using the same concentrations (10 μM) for both inhibitors. Results showed that S14161 almost completely blocked collagen- and thrombin-induced platelet aggregation. However, LY249002 only weakly inhibited platelet aggregation induced by collagen, and has no significant inhibition on thrombin-induced platelet aggregation at this concentration (Fig. 2C &2D). A high concentration of LY249002 (25 μM) showed a comparable inhibition on platelet aggregation as S14161 (10 μM) (data not shown).
S14161 Inhibits Platelet Activation and Thrombus Formation

A

50% Aggregation (%)

Collagen (2μg/ml)

LY294002 (μM)

1min

B

50% Aggregation (%)

Thrombin (0.1U/ml)

LY294002 (μM)

1min

C

50% Aggregation (%)

Collagen (2μg/ml)

LY294002 (10μM)

S14161 (10μM)

1min

D

50% Aggregation (%)

Thrombin (0.1U/ml)

LY294002 (10μM)

S14161 (10μM)

1min
In addition, we examined whether S14161 was effective in disrupting platelet aggregation induced by high doses of collagen or thrombin. We preincubated platelets with the minimal concentrations of S14161 (2.5 μM) that significantly inhibits platelet aggregation induced by collagen based on Figure 1A. Different concentrations of collagen (1, 2, or 10 μg/mL) were used to induce platelet aggregation. Results showed that 2.5 μM of S14161 did not inhibited platelet aggregation when collagen concentration reached to 10 μg/ml (Fig. 3A). Similarly, 5 μM of S14161 was found to loss its ability to inhibit platelet aggregation when thrombin concentrations reached to 0.2 U/ml (Fig. 3B). Therefore, S14161 was unable to disrupt platelet aggregation induced by higher doses of agonists.

S14161 Inhibits Platelet Activation and Thrombus Formation

To examine whether the inhibitory effect of S14161 on agonist-induced platelet aggregation is due to its potential toxicity to platelets, we performed an AlamarBlue assay which is based on the reducing power of living platelets that reduces the resazurin, a major component of AlamarBlue, to resorufin, a compound that is highly fluorescent. Platelets were exposed to S14161 for 15 minutes at 37°C and then incubated with AlamarBlue cell viability reagent for 4 hours at 37°C. Results showed that no decreases in the fluorescence intensity in the platelet samples treated with S14161 at 2.5, 5, or 10 μM compared to the vehicle control, indicating that treatment of platelets with S14161 in our

Figure 2. S14161 inhibited platelet aggregation more potently than LY249002. Gel-filtered human platelets (2.5×10⁸/mL) were preincubated for 10 minutes with different concentrations of LY249002 (10 μM, 20 μM and 40 μM) (A, B) or equal concentration of S14161 or LY249002. Platelet aggregation was initiated with collagen (2 μg/mL), thrombin (0.1 U/mL). The aggregation curves are the representatives of at least three individual experiments. Means ± standard errors of the mean of platelet aggregation percentage from three experiments are plotted in the bar charts; *P<0.05, **P<0.01 and ***P<0.001 as compared with control. N.S. means no significance (n = 3).
doi:10.1371/journal.pone.0102394.g002

Figure 3. S14161 was unable to disrupt platelet aggregation induced by higher doses of agonists. Gel-filtered platelets (2.5×10⁸/ml) were pre-incubated for 10 min with S14161 (2.5 μM or 5 μM). Platelet aggregation was initiated with different concentration of collagen (1 μg/ml, 2 μg/ml, and 10 μg/ml) (A) or with thrombin (0.05 U/ml, 0.1 U/ml, and 0.2 U/ml) (B). The data are representatives of at least three individual experiments.
doi:10.1371/journal.pone.0102394.g003
experimental system does not cause significant toxicity to platelets (Fig. 4A).

To evaluate whether the inhibition of platelet aggregation by S14161 is due to platelet apoptosis because S14161 has been shown to induce myeloma and leukemia cell apoptosis [23], we performed an Annexin V staining assay in which Annexin V specifies phosphatidylserine (PS) exposure on the outside of plasma membrane. The results showed that the percentage of Annexin V positive platelets was not significantly changed by S14161 (Fig. 4B). In contrast, as a positive control, calpain activator
dibucaine induced platelet apoptosis [31]. Thus, it was confirmed that the inhibitory effect of S14161 on platelet aggregation does not result from its apoptotic effect.

**S14161 inhibits PI3K/AKT/GSK3β signaling in platelets**

PI3K is a critical transmitter of intracellular signaling during platelet activation. Because the PI3K pathway is the most susceptible signaling pathway to S14161 [23], we further investigated how S14161 inhibits PI3K signaling in platelets. Gel-filtered human platelets were preincubated with or without S14161 (2.5 μM, 5 μM and 10 μM) or LY294002 (10 μM). Then, platelets were stimulated with collagen (2 μg/mL), thrombin (0.1 U/mL) or U46619 (1 μM) for 3 min with stirring at 1000 r.p.m. in an aggregometer at 37°C. Platelets were lysed, and immunoblotted using the corresponding antibodies recognizing total or phosphorylated AKT (Ser473 or Thr308) and phosphorylated GSK3β (Ser9). Densitometric band scanning was performed using an Odyssey Infrared Imaging System (LI-COR Biosciences). Data are representatives of at least 3 independent experiments.

doi:10.1371/journal.pone.0102394.g005
As S14161 showed a more potent inhibition in platelet aggregation, we compare its potency in inhibition of AKT phosphorylation with LY294002 as well. The same dose of the two compounds (10 μM) was used to pretreat platelets that were challenged by collagen, thrombin, and U46619. However, S14161 showed a comparable potency with LY294002 in inhibiting AKT phosphorylation (Fig. 5D–5F).

Influence of S14161 on platelet alpha-granule secretion and integrin inside-out signaling

To examine the effects of S14161 on platelet secretion, human platelets were pre-incubated with S14161 (10 μM) in the presence of fluorescent PE-conjugated P-selectin antibody and then challenged with convulxin (0.5 nM) for 15 minutes. P-selectin expression on platelets was monitored by flow cytometry. Results showed that S14161 inhibited convulxin-induced P-selectin expression by 67.5% (P < 0.001) (Fig. 6A). To investigate whether S14161 affected integrin inside-out signaling, we examined the effects of S14161 on integrin αIIbβ3 activation using soluble fibrinogen, which can bind to activated integrin αIIbβ3. Results showed that S14161 inhibited convulxin-induced platelet integrin activation by 68.3% (P < 0.001) (Fig. 6B).

To examine the inhibitory effect of S14161 on platelet alpha-granule secretion and integrin inside-out signaling induced by other common agonists such as thrombin, we performed p-selectin expression and fibrinogen binding assays using thrombin (0.1 U/mL) as an agonist. We showed that S14161 inhibited thrombin-induced platelet alpha-granule secretion and integrin inside-out signaling (Fig. 6C & 6D). Additional experiments showed that lower doses of S14161 (2.5 and 5 μM) also showed significant inhibition on convulxin-induced P-selectin expression and fibrinogen binding to a lesser extent. Although the same doses of S14161 showed significant inhibition for convulxin-induced fibrinogen binding, this inhibition did not occur for thrombin-induced fibrinogen binding (data not shown). Taken together, these data suggested that platelet secretion and integrin inside-out signaling were modulated by S14161.

Effects of S14161 on integrin outside-in signaling in platelets

As S14161 showed potent inhibition of platelet aggregation and fibrinogen binding, reflecting platelet inside-out signaling, we further asked whether S14161 could affect integrin outside-in signaling. Platelet spreading on immobilized fibrinogen assay was performed. As shown in figure 7A, the average surface coverage of vehicle-treated platelets was 12.79±2.91 μm², which was significantly reduced by S14161 in a dose dependent manner. At 10 μM, S14161 reduced platelet surface coverage by 61.3% (4.95±0.27 μm²) as compared with the vehicle control. Platelet clot retraction is an essential step in platelet thrombus consolidation and is initiated after platelet activation as a late consequence of integrin outside-in signaling. It also relies on an efficient extracellular fibrinogen-integrin interaction as well as a stable integrin-cytoskeletal association [28]. To investigate whether S14161 interferes with this important platelet function, we performed platelet clot retraction assay using PRP pretreated with S14161 (10 μM) or vehicle. Fibrin clot was induced at 37°C by the addition of thrombin to PRP and the subsequent platelet-dependent clot retraction was monitored over a 90-minute time period. As shown in figure 7B, the fibrin clot in the vehicle control tubes underwent a time-dependent retraction that started at 15 minutes and was completed at 90 minutes. The presence of S14161 at 10 μM resulted in a significant delay of clot retraction.

Inhibition of platelet adhesion on collagen-coated surfaces under flow by S14161

To further examine the inhibitory effect of S14161 on platelet adhesion on a collagen-coated surface, we perfused anticoagulated blood that had been labeled by calcein-AM and preincubated with S14161 over a collagen-coated surface in the microfluidics flow chamber (1000 s⁻¹). The fluorescence intensity from platelets on the collagen surface was calculated and data analysis showed that at a shear rate of 1000 s⁻¹, S14161 (10 μM) inhibits platelet accumulation by 77.6% (P < 0.01), 85.4% (P < 0.001), and 88.9% (P < 0.001) at 30 s, 90 s, and 180 s, respectively (Fig. 8A).

S14161 significantly affects thrombus formation, but not hemostasis, in vivo

To make sure that S14161 could be used for the in vivo animal studies on its potential inhibitory effect on thrombus formation as well as for the future clinical study, we performed a series of platelet aggregations using PRP, showing that S14161 significantly inhibited platelet aggregation induced by collagen (2 μg/mL) and U46619 (1 μmol/L) in human and mouse PRP (data not shown). To test whether S14161 inhibits arterial thrombus formation in vivo, S14161 (2 mg/kg) (n = 9) or vehicle (n = 8) was administered intraperitoneally to mice (6–8 weeks) and the time to occlusion of the carotid artery after application of 7.5% FeCl₃ for 2 minutes was measured using VisualSonics View 2100. Results showed that S14161-treated mice significantly extended the first occlusion time (5.05±0.99 min, N = 9) when compared to the vehicle-injected mice (3.72±0.95 min, n = 8) (P < 0.05) (Fig. 8B). To examine whether S14161 affects hemostasis while inhibiting platelet activation and thrombus formation, tail-bleeding time was evaluated. Results showed that S14161 did not significantly prolong the tail bleeding time (151.8±73.6 sec; n = 12) in mice that received a dose of 2 mg/kg S14161 compared to the vehicle-treated mice (139.6±71.3 sec; n = 10) (Fig. 8C). Therefore, S14161 appears to inhibit thrombus formation, but not cause a prolonged bleeding time.

Discussion

In this study we showed that S14161 inhibits platelet aggregation in the presence of a variety of platelet agonists including collagen, thrombin, ADP and U46619. S14161 also inhibits platelet secretion, integrin activation, and platelet adhesion on a collagen surface. Mechanistically, S14161 inhibits platelet function by suppressing PI3K/AKT signaling pathway. In vivo studies showed that S14161 prolongs the occlusion time upon vascular injury without bleeding tendency.

We previously showed that S14161 is a novel chromene-based inhibitor of pan-class I PI3Ks that inhibits the production of PI(3,4,5)P3 thus suppressing PI3K/AKT signaling transduction.
A

S14161 Inhibits Platelet Activation and Thrombus Formation

B
that IC50 of S14161 (PI3K isoforms) is 1.4 nM, which are higher than LY294002 (IC50: 1.4 μM) [33], the first synthetic prototypic inhibitor of pan-PI3K. However, our multiple sets of experiments showed that its potency in inhibiting PI3K isoforms with an IC50 of around 65 to 110 nM of thrombin. Clot retraction was monitored over time, and photographs of the clots were taken at different time points. The histograms of the clot size were generated from the photographs by calculating the ratio of the surface area of the retracted clot versus that of the initial clot. *P<0.05 and **P<0.01 compared with vehicle control (n = 3).

Figure 7. Effects of S14161 on platelet spreading on immobilized fibrinogen and fibrin clot retraction. (A) Gel filtered human platelets (2 x 10^9/mL) were preincubated with S14161 (2.5 μM, 5 μM and 10 μM) or vehicle for 30 min at 37°C and allowed to spread on fibrinogen-coated slides. Images were obtained with an Olympus fluorescence microscope. Statistical data were derived from quantitative results (means ± SEM) calculated from the mean of the average surface area of individual platelets from 3 separate experiments. ***P<0.001 vs. vehicle control. (B) Platelet rich plasma was incubated with S14161 (10 μM) or vehicle. Fibrinogen (2 mg/mL) was added and fibrin clot formation was initiated by adding 1 U/mL of thrombin. Clot retraction was monitored over time, and photographs of the clots were taken at different time points. The histograms of the clot size were generated from the photographs by calculating the ratio of the surface area of the retracted clot versus that of the initial clot. *P<0.05 and **P<0.01 compared with vehicle control (n = 3).

P13Ks form the lipid second messenger PI(3,4,5)P3 at the plasma membrane upon platelet activation and recruit phosphoinositide-dependent protein kinase 1 (PDK1) and AKT. PKD1 phosphorylates AKT at Thr308 and AKT is subsequently phosphorylated on Ser473 by mTORC2, a key downstream mediator of P13K-dependent signaling, resulting in maximal AKT activity [34,35]. In our study, S14161 decreases phosphorylation of AKT at both Thr308 and Ser473 sites in a similar potency in response to collagen, thrombin, and U46619. Inhibition of S14161 by Li Z, et al [37]. We chose platelet spreading, an early response to collagen, thrombin, and U46619. Inhibition of S14161 by Li Z, et al [37]. We chose platelet spreading, an early event that occurs during platelet aggregation and PI(3,4,5)P3 generation. It is reasonable to suspect that S14161 may have side effects as other P13K inhibitors do when they are used as a therapeutic agent. However, our previous studies [23] and the data on platelets in the present study have shown that S14161 is a safe compound in the safety evaluation. S14161 delayed the growth of leukemia xenografts in nude mice within 10 days but did not show any obvious toxicity. Although S14161 induces apoptosis in myeloma and leukemia cell lines and primary patient samples, it does not induce apoptosis in platelets. The other potential issue needs to be clear is the specificity of S14161 in inhibiting platelet aggregation especially as it shows discrepancy in inhibiting platelet activation and thrombus formation. The benefit of an antithrombotic agent has to be considered under the balance between efficacy in reduction of symptomatic thrombotic events and the risk for hemorrhage. Our study confirmed that S14161 does not cause a prolonged bleeding time. It is reasonable to suspect that S14161 may have side effects as other P13K inhibitors do when they are used as a therapeutic agent. However, our previous studies [23] and the data on platelets in the present study have shown that S14161 is a safe compound in the safety evaluation. S14161 delayed the growth of leukemia xenografts in nude mice within 10 days but did not show any obvious toxicity. Although S14161 induces apoptosis in myeloma and leukemia cell lines and primary patient samples, it does not induce apoptosis in platelets. The other potential issue needs to be clear is the specificity of S14161 in inhibiting platelet aggregation especially as it shows discrepancy in inhibiting platelet aggregation and PI(3,4,5)P3 generation in vitro. However, in our previous work [23], we showed that it did not inhibit the enzymatic activities of other related kinases, including the mammalian target of rapamycin, the DNA-dependent protein kinase catalytic subunit, and phosphoinositide-dependent kinase-1. Further investigation need to be done for the specificity of S14161. In summary, this study demonstrated for the first time the inhibitory effect of S14161 on platelet activation and thrombus formation without significant bleeding tendency. Comparing to LY294002, S14161 displayed a more potent effect on inhibiting platelet aggregation potentially due to its better bioavailability in the natural system. Further study in comparing its antithrombotic effect and bleeding tendency with other well-studied P13K inhibitors would generate more information on its advantages in effectiveness and safety as it mainly affects platelet P13K/AKT signaling. Collectively, our data in this study and our previous reports clearly suggest that this chemical compound may be developed as a potential antiplatelet and antithrombotic agent for the prevention and treatment of thrombotic disease.
Figure 8. S14161 inhibited platelet adhesion on collagen-coated surfaces under flow ex vivo and thrombus formation in vivo, but not hemostasis. (A) Human whole blood was labeled with Calcein-AM, treated with (lower channels) or without (upper channels) S14161 (10 μM), and perfused over collagen-coated surface at a shear rate of 40 dyn/cm² (1000 s⁻¹). Platelet adhesion and aggregates were photographed. Data plotted are means ± standard errors of fluorescence intensity of three individual experiments (**P<0.01, ***P<0.001). Arrow indicates the flow direction. (B) S14161 (2 mg/kg) (n=9) or vehicle (n=8) was administered intraperitoneally to mice and time to occlusion of the carotid artery after the application of 7.5% FeCl₃ for two minutes was measured using Visual Sonics View 2100. Time to loss of blood flow was recorded. (C) S14161
Author Contributions
Conceived and designed the experiments: WY QL XM LZ. Analyzed the data: WY QL Q. Wang

References
1. Barret NE, Hollbrook L, Jones S, Kaiser VJ, Moraes LA, et al. (2008) Future innovations in anti-platelet therapies. Br J Pharmacol 154: 918–939.
2. Kaplan ZS, Jackson SP (2011) The role of platelets in atherothrombosis. Hematology Am Soc Hematol Educ Program 2011: 51–61.
3. Ruggeri ZM (2002) Platelets in atherothrombosis. Nat Med 8: 1227–1234.
4. Poole A GJ, Shutes A, van Vugt MJ, deWinkel JGJ, Saito T, et al. (1997) The Fc receptor-g chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBO J 16: 2333–2341.
5. Gibbins JM BS, Shutes A, van Vugt MJ, deWinkel JGJ, Saito T, et al. (1998) The p85 subunit of phosphatidylinositol 3-kinase associates with the Fc receptor gamma-chain and linker for activator of T cells (LAT) in platelets stimulated by collagen and convulxin. J Biol Chem 273: 34437–34443.
6. Reheman A, Yang H, Zhu G, Jin W, He F, et al. (2009) Plasma fibronectin depletion enhances platelet aggregation and thrombus formation in mice lacking fibronectin and von Willebrand factor. Blood 113: 1809–1817.
7. Yang H, Reheman A, Chen P, Zhu G, Hyun RO, et al. (2009) Fibronogen and von Willebrand factor-independent platelet aggregation in vitro and in vivo. J Thromb Haemost 4: 2230–2237.
8. Huang ZS, Zeng CL, Zhu JJ, Jiang L, Li N, et al. (2010) Salvianolic acid A inhibits platelet activation and arterial thrombosis via inhibition of phosphoinositide 3-kinase. J Thromb Haemost 8: 1383–1393.
9. Mehran R, Rao SV, Bhatt DL, et al. (2011) Identification of a calmodulin-binding domain in Sema4D that regulates its exodomain shedding in platelets. Blood 121: 4221–4230.
10. Prevost N, Woulfe D, Tanaka T, Brass LF (2002) Interactions between Eph kinases and ephrins provide a mechanism to support platelet aggregation once cell-to-cell contact has occurred. Proc Natl Acad Sci U S A 99: 9219–9224.
11. Li W, Tan Q, Yi W, Li Q, Ren L, et al. (2013) Glaucocalyxin A Inhibits Platelet Activation and Thrombus Formation Preferentially via G Proteins Signaling Pathway. PLoS One 8: e51290.
12. Su X, Mi J, Yan J, Flevari P, Lu Y, et al. (2008) RGT, a synthetic peptide corresponding to the integrin beta 3 cytoplasmic C-terminal sequence, selectively inhibits outside-in signaling in human platelets by disrupting the interaction of integrin alpha IIb beta 3 with Src kinase. Blood 112: 592–603.
13. Hong SS, Lee SA, Han KH, Hwang JS, Lee C, et al. (2008) euk-Kaurane diterpenoids from Iosodon japonicus. J Nat Prod 71: 1055–1058.
14. Zhai L, Bergmeier W, Wu J, Jiang H, Stalker TJ, et al. (2007) Regulated surface expression and shedding support a dual role for semaphorin 4D in platelet responses to vascular injury. Proc Natl Acad Sci U S A 104: 1621–1626.
15. Zhang W, Liu J, Sun R, Zhao L, Du J, et al. (2011) Calpain activator dibucaine induces platelet apoptosis. J Mol Biol Sci 12: 2125–2137.
16. Li D, August S, Woulfe DS (2008) GSK3beta is a negative regulator of platelet function and thrombosis. Blood 111: 3522–3530.
17. Vlahos CJ, Matter WF, Hui KY, Brown RF (1994) A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4morpholinoethoxy)-6-phenyl-1H-benzopyran-4-one (LY294002). J Biol Chem 269: 5241–5248.
18. Chen X, Zhang Z, Yang W, Li D, Zhang L, et al. (2013) PDK1 regulates platelet activation and arterial thrombosis. Blood 121: 3718–3726.
19. Moore SF, Hunter RW, Hers I (2011) mTORC2 protein complex-mediated Akt phosphorylation. Nature 378: 785–789.
20. Li Z, Delaney MK, O’Brien KA, Du X (2010) Signaling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol 30: 2341–2349.
21. Yang Y, Shi Z, Reheman A, Jiu JW, Li C, et al. (2012) Plant food delphinidin-3-glucoside significantly inhibits platelet activation and thrombosis: novel protective roles against cardiovascular diseases. PLoS One 7: e37233.
22. Lei X, Reheman A, Hou Y, Zhou H, Wang Y, et al. (2014) Antithrombotic, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis. Thromb Haemost 111: 279–289.

XM LZ. Contributed reagents/materials/analysis tools: SH Q, Wu XM LZ. Wrote the paper: WY QI, HH XM LZ.